Athenex Teams Up with Lilly for Two-Drug Gastric Cancer Trial

Athenex, a US-China pharma, will collaborate with Eli Lilly in a two-drug clinical trial for patients with advanced gastric and esophageal cancer. Athenex will contribute oraxol, its oral form of paclitaxel, and Lilly will add CYRAMZA ® , a vascular endothelial growth factor (VEGF) Receptor 2 antagonist. The Phase Ib trial, which will start in early 2017, will be conducted in the US and Asia. Athenex is building two manufacturing plants in Chongqing. More details.... Stock Symbol: (NYSE: LLY) Share this with colleagues: // //